logo Enovis.jpg
Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
September 09, 2024 15:50 ET | Enovis Corporation
WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the...
This is the fast lane by Enovis Foot & Ankle!
Enovis™ Introduces the Next Generation of Foot and Ankle Surgery Offerings at AOFAS Annual Meeting
September 05, 2024 08:00 ET | Enovis Corporation
Wilmington, DE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), an innovation-driven medical technology company, announced today it will unveil its new Tarsoplasty Percutaneous Lapidus...
logo Enovis.jpg
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures
August 20, 2024 08:00 ET | Enovis Corporation
WILMINGTON, DE, Aug. 20, 2024 (GLOBE NEWSWIRE) --  Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, announced today the expansion of its EMPOWR Revision Knee™ system to...
STAR® Ankle with e+™ Polyethylene
Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability
August 19, 2024 08:00 ET | Enovis Corporation
Wilmington, DE, Aug. 19, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, proudly unveils its Scandinavian Total Ankle Replacement (STAR®...
logo Enovis.jpg
Enovis to Participate in Upcoming Investor Conferences
August 12, 2024 16:10 ET | Enovis Corporation
Wilmington, DE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will...
logo Enovis.jpg
Enovis Announces Second Quarter 2024 Results
August 07, 2024 06:00 ET | Enovis Corporation
Continued strong momentum with second-quarter sales growth of 23% on a reported basis and strong adjusted margin expansionReported second-quarter net loss from continuing operations of $0.34 per share...
logo Enovis.jpg
Enovis Announces Time Change for Second Quarter 2024 Results Conference Call
July 25, 2024 06:00 ET | Enovis Corporation
Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming...
logo Enovis.jpg
Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
July 16, 2024 07:00 ET | Enovis Corporation
Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call...
logo Enovis.jpg
Enovis™ Releases AltiVate Reverse® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse®
July 12, 2024 08:00 ET | Enovis Corporation
AUSTIN, TX, July 12, 2024 (GLOBE NEWSWIRE) --  Enovis™ (NYSE: ENOV), a leading innovator in shoulder arthroplasty systems that help improve quality of life and restore movement, introduced today the...
logo Enovis.jpg
Enovis to Participate in Upcoming Investor Conferences
May 10, 2024 06:00 ET | Enovis Corporation
Wilmington, DE, May 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate...